Vitamins, antioxidants and endothelial function in coronary artery disease

Cardiovascular Drugs and Therapy

Volumn 16, Issue 5, 2002, Pages 401-409

  Hornig, Burkhard ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIOXIDANT; ARGININE; ASCORBIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; FLAVONOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE; PROBUCOL; TETRAHYDROBIOPTERIN; TUMOR NECROSIS FACTOR ALPHA;

AMINO ACID DEFICIENCY; BLOOD VESSEL TONE; CARDIOVASCULAR RISK; CELL ADHESION; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM; GRAPE JUICE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MONOCYTE; OXIDATIVE STRESS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; THROMBOCYTE AGGREGATION; TRANSLUMINAL CORONARY ANGIOPLASTY; VASODILATATION; VASOMOTOR REFLEX;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIOXIDANTS; ASCORBIC ACID; CORONARY DISEASE; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOSARTAN; NITRIC OXIDE; OXIDATIVE STRESS; RAMIPRIL; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; SUPEROXIDE DISMUTASE; VITAMINS;

EID: 0036999165     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022182201534     Document Type: Conference Paper

References (64)

1. Rudic RD, Shesely EG, Maeda N, Smithies O, Segal SS, Sessa WC. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest 1998;101:731-736.
2. Al Suwaidi J, Hamasaki S, Higano S, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000;101:948-954.
3. Neunteufl T, Priglinger U, Heher S, et al. Effects of vitamin E on chronic and acute endothelial dysfunction in smokers. J Am Coll Cardiol 2000;35:277-283.
4. Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilaator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-1906.
5. Xia Y, et al. Nitric oxide synthase generates super-oxide and nitric oxide in arginine-depleted cells leading to peroxynitrite - mediated cellular injury. Proc Natl Acad Sci 1996;93:6770-6774.
6. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74:1141-1148.
7. Rajagopalan S, Kurz S, Münzel T, et al. Antiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. J Clin Invest 1996;96:1513-1519.
8. Warnholtz A, Nickenig G, Schulz E, et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: Evidence for the involvement of the renin-angiotensin system. Circulation 1999;99:2027-2033.
9. Stralin P, et al. The interstitium of the human arterial wall contains very large amounts of extracellular superoxide dismutase. Arterisclerosis Thromb Vasc Biol 1995;15:2032-2036.
10. Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF, Vita JA. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996;93:1107-1113.
11. Motoyoma T, Kawano H, Kugiyama K, et al. Endothelium-dependent vasodilation in the brachial artery is impaired in smokers: Effect of vitamin C. Am J Physiol 1997;273:1644-1650.
12. Hornig B, Arakawa N, Kohler C, Drexler H. Vitamin C improves endothelial function in patients with chronic heart failure. Circulation 1998;97:363-368.
13. Duffy SJ, Gokce N, Holbrook M, et al. Effect of ascorbic acid treatment on conduit vessel endothelial dysfunction in patients with hypertension. Am J Physiol 2001;279:528-534.
14. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998;97:2222-2229.
15. Ting, HH, Timimi FK, Boles KS, et al. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin dependent diabetes mellitus. J Clin Invest 1996;97:22-28.
16. Timimi FK, Ting HH, Haley, et al. Vitamin C improves endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol 1998;31:552-557.
17. Beckmann JA, Goldfine AB, Gordon MB, Craefer MA. Ascorbate restores endothelium-dependent vasodilation impaired by acute hypergglycemia in humans. Circulation 2001;103:1618-1623.
18. Ellis GR, Anderson RA, Lang D, et al. Neutrophil superoxide anion-generating capacity, endothelial function and oxidative sress in chronic heart failure: Effects of short- and long-term vitamin C therapy. J Am Coll Cardiol 2000;36:1474-1482.
19. Solzbach U, Hornig B, Jeserich M, Just H. Vitamin C improves endothelial dysfunction of epicardial coronary arteries in patients with essential hypertension. Circulation 1997;96:1513-1519.
20. Kaufmann PA, Gnecchi-Ruscone T, di Terlizzi M, et al. Coronary heart disease in smokers. Vitamin C restores coronary microcirculatory function. Circulation 2000;102:1233-1238.
21. Jackson TS, Xu A, Vita JA, Keaney JF. Ascorbate prevents the interaction of superoxide and nitric oxide only at very high physiological concentrations. Circulation Research 1998;83:916-922.
22. Duffy SJ, Gokce N, Holbrook M, et al. Treatment of hypertension with ascorbic acid. Lancet 1999;354:2048-2049.
23. Langlois M, Duprez D, Delanghe J, De Buyzere M, Clement DL. Serum vitamin C concentration is low in peripheral arterial disease and is associated with inflammation and severity of atherosclerosis. Circulation 2001;103:1863-1868.
24. Khaw K-T, Bingham S, Luben R, Wareham N, Oakes S, Day N. Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: A prospective population study. Lancet 2001;357:657-663.
25. Huang A, et al. JBC 2000;275:17399-17406.
26. Pritchard KA, Groszek L, Smalley DM, et al. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res 1995;77:510-518.
27. Heitzer T, Broekhoff C, Mayer B, et al. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: Evidence for dysfunctional nitric oxide synthase. Circulation Research 2000;86:36-41.
28. Stroes E, Kastelein J, Cosentino F, et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 1997;99:41-46.
29. Tiefenbacher CP, Bleeke T, Vahl C, et al. Endothelial dysfunction of coronary resistance arteries is improved by tetrahydrobiopterin in atherosclerosis. Circulation 2000;102:2172-2176.
30. Ueda S, Matsuoka H, Miyazaki H, Usui M, 0kuda S, Imaizumi T. Tetrahydrobiopterin restores endothelial function in long-term smokers. J Am Coll Cardiol 1999;35:71-75.
31. Anderson T, Meredith I, Yeung A, Frei B, Selwyn AP, Ganz P. The effect of cholesterol lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-493.
32. Kinlay S, Fang JC, Hikita H, et al. Plasma tocopherol and coronary endothelium-dependent vasodilator function. Circulation 1999;100:219-221.
33. Evans M, Anderson RA, Graham J, et al. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation 2000;101:1773-1778.
34. Gilligan DM, Sack MN, Guetta V, et al. Effect of antioxidant vitamins on low density lipoprotein oxidation and impaired endothelium-dependent vasodilation in patients with hypercholesterolemia. J Am Coll Cardiol 1994;24:1611-1617.
35. Heitzer T, Yla Herttuala S, Wild E, Uoma J, Drexler H. Effect of vitamin E on endothelial vasodilator function in patients with hypercholesterolemia, chronic smoking or both. J Am Coll Cardiol 1999;33(2):499-505.
36. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153.
37. Stein JH, Keevil JG, Wiebe DA, et al. Purple grape juice improves endothelial function and reduces the susceptibility of LDL-cholesterol to oxidation in patients with coronary artery disease. Circulation 1999;100:1050-1055.
38. Flesch M, Schwarz A, Boehm M. Divergent effects of red and white wine on endothelium-dependent relaxation of human coronary arteries. Circulation 1997;96:I-341(abstract).
39. Renaud S, De Lorgeril M. Wine, alcohol, platelets and the french paradox for coronary heart disease. Lancet 1992;339:1523-1526.
40. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbitiy in patients with left ventricular dysfunction after myocardial infarctions: Results of the survival and ventricular enlargement trial. N Eng J Med 1992;327:669-677.
41. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-1178.
42. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbitiy of survivors of acute mycardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-828.
43. Mancini GBF, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996;94:258-265.
44. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of ACE-inhibitors in humans. Circulation 1997;95:1115-1118.
45. Hornig B, Arakawa N, Hausmann D, Drexler H. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998;98(25):2442-2448.
46. Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotensin-II antagonism and calcium-channel blockade on flow-mediated vasodilation in patients with coronary artery disease (BANFF-study). J Am Coll Cardiol 1999;35:60-66.
47. Pellacani A, Brunner HR, Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci 1994;87:567-574.
48. Groves P, Kurz S, Just H, Drexler H. Role of endogenous bradykinin in human coronary vasomotor control. Circulation 1995;92:3424-3430.
49. Hornig B, Landmesser U, Kohler C, et al. Comparative effect of ACE-inhibition and angiotensin II-type 1-receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease - Role of superoxide dismutase. Circulation 2001;103:799-805.
50. Prasad A, Tupas-habib T, Schenke WH, et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclöerosis. Circulation 2000;101:2349.
51. Cheetham C, Collis J, O'Driscoll G, Stanton K, Taylor R, Green D. Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes. J Am Coll Cardiol 2000;36:1461-1466.
52. O'Discroll G, Green D, Taylor RR. Simvastatin, an HMGcoenzyme a reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95:1126-1131.
53. Laufs U, Fata VL, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-1135.
54. Nickening G, Bäumer AT, Temur Y, Kebben D, Jockelhovel F, Böhm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999;100:2131-2134.
55. Gould KL, Martucci JP, Goldberg DI, et al. Short-term cholersterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipirydamol in patients with coronary artery disease - A potential noninvasive marker of healing coronary endothelium. Circulation 1994;89:1530-1538.
56. Mostaza JM, Gomez MV, Gallardo F, et al. Cholesterol reduction improves myocardial perfusion abnormalities in patients with coronary artery disease and average cholesterol levels. J Am Coll Cardiol 2000;35:76-82.
57. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease, Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
58. Sacks FM, Pfeffer MA, Lemuel AM, et al. The effect of Pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
59. The Long-Term Invervention with Pravastatin in Ischemic Heart Failure (LIPID) Study Group. Prevention of cardiovascular events and death with Pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;39:1349-1357.
60. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999;341:70-76.
61. Rieder MJ, Carmona R, Krieger JE, Pitchard KA, Jr, Greene AS. Supression of angiotensin-converting enzyme expression by shear stress. Circ Res 1997;80:312-319.
62. Heitzer T, Just H, Munzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation 1996;94:6-9.
63. Ting HH, Timimi FK, Haley EA, Roddy MA, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia. Circulation 1997;95:2617-2622.
64. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbitiy in patients with left ventricular dysfunction after myocardial infarctions: Results of the survival and ventricular enlargement trial. N Eng J Med 1992;327:669-677.